Immunology Startup Boulevard Bio Raises $65M, Adds Chinese Drug Candidate to Pipeline
Boulevard Bio has secured $65 million in funding to advance its immunology pipeline, which includes two internally discovered immune-resetting drugs and an investigational asset from China targeting IgA nephropathy. The company is specifically eyeing Vera Therapeutics' drug for immunoglobulin A nephropathy (IgAN) as a key addition. This move reflects a growing trend of biotechs acquiring Chinese-developed therapies.
Related stories
OmicsBank raises $2.25M for cross-border patient data services · Drug development
Immunology drug developer secures $820M in reverse merger push · Drug development
BioMarin acquires early-stage bone disease candidate in modest deal · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drug.” Browse more stories.